ADMdx will present the results of machine learning classification of different Alzheimer’s disease variants and non Alzheimer’s dementias using three different modalities:  structural MRI, glucose metabolism using FDG PET, and early timeframes of amyloid PET scans.  This work was conducted in collaboration with researchers from the Memory and Aging Center of the University of California, […]

ADMdx will present the results of machine learning classification of brain images from impaired and unimpaired boxers, and their differentiation from Alzheimer’s disease images, at the Alzheimer’s Association International Conference on July 22, 2018. This work was conducted in collaboration with Dr. Charles Bernick and other researchers at the Cleveland Clinic, using structural MRI scans […]

ADMdx has been awarded a Small Business Innovation Research grant from the National Institutes of Aging, focused on the prediction of tau burden in the brain using MRI scans and machine learning.  PET tracers for tau have made it possible to measure abnormal tau accumulation, one of the hallmark pathologies of Alzheimer’s disease.  Using tau […]

The results of our collaborative work led by Dr. Lisa Mosconi at Weill Cornell Medical School have been published in the April issue of the journal Neurology. Findings showed that lower adherence to a Mediterranean diet was associated with progressive abnormalities in glucose metabolism (measured using FDG PET imaging) and in amyloid (measured using amyloid PET […]

Our collaborative work led by Dr. Lisa Mosconi of Weill Cornell Medical College has been published in the March issue of the British Medical Journal, titled “Lifestyle and vascular risk effects on MRI-based biomarkers of Alzheimer’s disease: a cross-sectional study of middle-aged adults from the broader New York City area”.  In this study, brain image […]

ADMdx presents the results of our collaborative work with Siemens Healthcare in quantifying the effects of PET image reconstruction on measured amyloid burden.

ADMdx presented its work in applications of machine learning to critical drug development questions at the American College of Neuropsychopharmacology (ACNP) Conference held in Palm Springs, CA, on December 5, 2017.  Examples presented included differentiation of dementias, prediction of cognitive decline, and dose-response of two neuropsychiatric therapeutics.

Results of our application of machine learning to the DIAN early-onset Alzheimer’s disease data set were presented at the Clinical Trials in Alzheimer’s Disease on November 2, 2017, in Boston, MA.

ADMdx to present findings in tau imaging at the 2017 Alzheimer’s Association International Conference (AAIC). This work identifies relationships between the emergence of AD-related hypometabolism, amyloid status, and tau burden across the spectrum of preclinical, prodromal, and dementia stage Alzheimer’s disease.

Dawn Matthews to speak at Traumatic Brain Injury (TBI) symposium, where she will describe Opportunities and Challenges in imaging of TBI. The symposium is focused on the need for initiatives in the diagnosis and treatment of the brain trauma occurring in athletes, military, and other personnel.